Abstract
Iron deficiency (ID), with or without anemia, is commonly found worldwide and affects the health and wellbeing of pregnant and nonpregnant women. Symptoms of ID- which include fatigue, pica (ice craving), restless legs syndrome, poor concentration and work function, increased susceptibility to infection, and cardiovascular stress- can cause significant morbidity and reduced quality of life. The etiologies of iron deficiency in women are usually specific to each community. In the developing world, iron deficiency is usually associated with poor iron intake and parasitic infections, whereas in higher income regions, iron deficiency is typically the result of heavy, abnormal uterine bleeding, and pregnancy. Iron-poor diets and poor iron absorption resulting from gut disorders can also play a role. Diagnosis of iron deficiency is usually straightforward and characterized by a low ferritin level; however, the diagnosis can be challenging in women with concomitant inflammatory disorders, in which case a low percent transferrin saturation, performed after an overnight fast, can inform on the need for iron. Therapy is frequently initiated with oral iron salts; however, use of these oral regimens is commonly associated with adverse events, mostly gastrointestinal in nature, that have been shown to adversely impact compliance, continuation, and the achievement of therapeutic goals. A further impediment to the effectiveness of oral iron is its poor absorption because of comorbidity (i.e., celiac disease, gastritis, etc.), surgery (bariatric), or physiologic inhibitory mechanisms. As such, intravenous (IV) iron regimens are increasingly being used to treat ID, as such regimens have been shown to avoid the gastrointestinal adverse events commonly associated with oral regimens. Indeed, IV iron has been shown to provide adequate iron replacement in women with functional iron deficiencies as well as those with ID resulting from inflammatory disorders- patients often resistant to oral iron therapy. More recent IV iron regimens have been shown to provide iron replacement in a safe and effective manner, being associated with more salutary adverse event profiles than earlier IV iron regimens. In fact, these iron regimens can provide a complete replacement dose in a single 15–60-min visit.
Similar content being viewed by others
References
Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260–72.
Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615–24.
Camaschella C. Iron deficiency: new insights into diagnosis and treatment. Hematol Am Soc Hematol Educ Program. 2015;2015:8–13.
Daru J, Cooper NA, Khan KS. Systematic review of randomized trials of the effect of iron supplementation on iron stores and oxygen-carrying capacity in pregnancy. Acta Obstet Gynecol Scand. 2016;95:270–9.
Percy L, Mansour D, Fraser I. Iron deficiency and iron-deficiency anemia in women’s health. Best Pract Res Clin Obstet Gynaecol. 2017;40:55–67.
Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World J Gastroenterol. 2009;15:4617–26.
Zhao L, Zhang X, Shen Y, et al. Obesity and iron deficiency: a quantitative meta-analysis. Obes Rev. 2015;16:1081–93.
Cepeda-Lopez AC, Aeberli I, Zimmermann MB. Does obesity increase risk for iron deficiency? A review of the literature and the potential mechanisms. Int J Vit Nutr Res. 2010;80:263–70.
Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105–22.
D’Angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013;48:10–5.
Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation? Wien Med Wochenschr. 2016;166:411–23.
Breymann C, Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and mananagement. Hematol Am Soc Hematol Educ Program. 2017;8:152–9.
Mahey R, Kriplani A, Mogili KD, et al. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstet. 2016;133:43–8.
Ferrara M, Coppola L, Coppola A, Caprizzi M. Iron deficiency in childhood and adolescence: retrospective review. Hematology. 2006;11:183–6.
Whitaker L, Critchley HOD. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:54–65.
Magnay JL, O’Brien S, Gerlinger C, Seitz C. A systematic review of methods to measure menstrual blood loss. BMC Women’s Health. 2018;18:142–55.
Munro MG, Critchley HOD, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:3–13.
El-Andaloussi A, Chaudhry Z, Al-Hendy A, et al. Uterine fibroids: Bridging genomic defects and chronic inflammation. Semin Reprod Med. 2017;35:494–8.
Jimenez JM, Gache C. Management of iron deficiency anaemia in inflammatory bowel disease. Acta Haematol. 2019;142:30–6.
Georgieff MK. Iron deficiency in pregnancy. Am J Obstet Gynecol. 2020;223(4):516–24.
Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013;3:a011866.
Milman N. Postpartum anemia I: definition, prevalence, causes and consequences. Ann Hematol. 2011;90:1247–53.
Milman N. Postpartum anemia II: prevention and treatment. Ann Hematol. 2012;91:143–54.
Gomez-Ramirez S, Bisbe E, Shander A, et al. Management of perioperative iron deficiency anemia. Acta Haematol. 2019;142:21–9.
Pratt JJ, Khan KS. Non-anemic iron deficiency—a disease looking looking for recognition of diagnosis: a systematic review. Eur J Haemotol. 2015;96:618–28.
Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54:306–15.
Stoffel N., Cercamondi C, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017; E524-E533
Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transpl. 2014;29:833–42.
Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93:683–90.
Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719–28.
Seid MH, Butcher AD, Chatwani A. Ferric carboxymaltose as treatment in women with iron-deficiency anemia. Anemia. 2017;2017:9642027. https://doi.org/10.1155/2017/9642027.
Camaschella C. Iron deficiency anemia. N Engl J Med. 2015;372:1832–43.
Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107:16–30.
Kim YH, Ching HH, Kang S-B, et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematol. 2009;121:37–41.
Lee S, Ryu KJ, Lee ES, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: an open-label, multicenter, randomized study. J Obstet Gynaecol Res. 2019;45:858–64.
Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94:1007–14.
Wolf M, Auerbach M, Kalra PA. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: the FERWON-IDA/NEPHRO trials. Am J Hematol. 2021;96:E11–5.
Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062–8.
DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142:8–12.
Freidman AJ, Shander A, Martin SR, et al. Iron deficiency anemia in women: a practical guide to detection, diagnosis, and treatment. Obstet Gynecol Surv. 2015;70:342–53.
DeLoughery TG. Iron deficiency anemia. Med Clin North Am. 2017;101:319–32.
Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90:12–23.
Acknowledgements
Funding
No funding or sponsorship was received for publication of this article.
Author contributions
Dr. Shulman and Dr. Moisidis-Tesch contributed equally to concept and design, writing, and editing.
Disclosures
Dr. Shulman and Dr. Moisidis-Tesch both have nothing to disclose.
Compliance with ethics guidelines
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moisidis-Tesch, C.M., Shulman, L.P. Iron Deficiency in Women’s Health: New Insights into Diagnosis and Treatment. Adv Ther 39, 2438–2451 (2022). https://doi.org/10.1007/s12325-022-02157-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-022-02157-7